Hikma’s Injectables Business Expands As It Completes Custopharm Acquisition
Completion Of $425m Deal Comes Shortly After FTC Approved The Transaction
Executive Summary
Hikma has completed its acquisition of Custopharm, expanding its US injectables business as the company continues to look for more deals.